The EMA evaluates the booster dose of Johnson & Johnson vaccine in people over 18 years of age

The European Medicines Agency (EMA) began on Monday to evaluate a request from Janssen, the American pharmaceutical company Johnson & Johnson, to administer a booster injection of its single-dose vaccine against COVID-19 two months after the first in those over 18 years of age.

SIGHT: “There is always a risk of a new variant”: Europe increases coronavirus sequencing

The Committee for Medicinal Products for Human Use (CHMP) is already studied, in a process of “Accelerated assessment”, data presented by the company to support the need for a second dose, including the results of one who received a second injection or a placebo two months after the initial dose.

The EMA could announce its findings, unless additional information is needed from the pharmacist.

SIGHT: Health policies based on science and evidence, by Elmer Huerta

Janssen’s vaccine, which is based on an adenoviral vector derived from an adenovirus that causes the common cold in humans, has already been authorized in the European Union (EU) since last March, but with a single dose, in people over 18 years of age, the scenario that was effective in clinical trials.

In addition, the agency has already endorsed the booster dose in adults of the Pfizer / BioNtech and Moderna vaccines, both based on messenger RNA, although the decision to use this injection is the prerogative of the national authorities of each country, based on different factors, including the spread of the virus, the availability of vaccines, and the capacity of the national health system.

SIGHT: The scientific race to find people resistant to COVID-19

Last week, Marco Cavaleri, head of Vaccination Strategy at the EMA, stressed that “The booster doses are going to play an important part in the vaccination strategy” ongoing in the EU, especially given the increase in infections and hospitalizations in the region due to COVID-19.

In addition, it specified that the interval of at least six months between the second and third doses has been concluded from the available data, but “It would be fully understood if countries decide to bet on and consider an earlier point to administer that booster dose ”.

• “There is always a risk of a new variant”: Europe increases coronavirus sequencing
• Health policies based on science and evidence, by Elmer Huerta
• The scientific race to find people resistant to COVID-19
• How long do immune cells against COVID-19 last after vaccination?
• COVID-19 | Is herd immunity the goal we should pursue with vaccination?
• A fish vendor from Wuhan market is the first known case of COVID-19, study reveals
• COVID-19 | Masks, confinement and hand washing: are there more effective measures than others?
• Immunotherapy with killed bacteria reduces mortality and boosts vaccines against COVID-19
• Pfizer and Moderna vaccines may give false positives for COVID-19
• AstraZeneca Antibody Drug 83% Protects Against COVID-19 for Six Months
• Pfizer and Moderna vaccines may give false positives for COVID-19
• How is the first drug against COVID-19 that China would have ready in December?
• 82% of COVID-19 cases in Peru are detected in unvaccinated people
• Why China maintains its goal of not registering any coronavirus infection
• Pfizer agrees to facilitate global access for its COVID-19 pill
• COVID-19 | Italy raids anti-vaccines for promoting violence on the internet
• COVID-19 | What is Austria looking for by confining only the unvaccinated?

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn